drug-resistant epilepsy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age greater than or equal to 18 years old and less than or equal to 80 years old; 2. Patients with drug-resistant epilepsy; 3. There was no change in antiseizure medications (ASMs) dose for at least 30 days prior to study participation 4. Patients sign informed consent forms 5. Be able and willing to cooperate to complete the record.
Exclusion criteria
Exclusion criteria: 1. Any serious mental disorder (such as schizophrenia or delusional disorder); 2. Brain injury with loss of consciousness or suicidality; 3. Pacemaker implants or other metal implant devices; 4. Concomitant progressive central nervous system disease or severe heart, liver, kidney, and blood disorders; 5. Presence of cardiovascular disease (such as significant arrhythmias, heart failure or ischemic heart disease); 6. There is a history of non-epileptic seizures; 7. Current or former participants in other percutaneous electrical stimulation therapy for less than 3 months; 8. Pregnancy and lactation or inadequate contraception; 9. Have a history of facial pain or trigeminal nerve pain; 10. MRI contraindications: metal implantation in the body, claustrophobia, etc; 11. Smoking addicts, alcoholics; 12. The patient or family member cannot fully comply with the treatment plan; 13. Participants in other clinical trials; 14. Refusal to sign informed consent.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Changes in anxiety and depressive state scores;Changes in the degree of seizures;Changes in sleep quality scores;Changes in cognitive function scores;Quality of life score changes;Assessment of brain function and autonomic nervous function; | — |
Primary
| Measure | Time frame |
|---|---|
| Treatment response (50% reduction in seizure frequency was defined as effective); | — |
Countries
China